Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

December 2021 | 108 pages | ID: A11B7F304179EN
GMD Research

Abstracts

Asia Pacific monoclonal antibodies market will grow by 12.8% annually with a total addressable market cap of $414 billion over 2021-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.

Highlighted with 31 tables and 51 figures, this 108-page report “Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.

Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.

• Human
• Humanized
• Chimeric
• Murine

Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.

• Branded mAbs
• Biosimilar mAbs

Based on Production Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.

• In Vitro Production
• In Vivo Production

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.

• Cancer
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Ovarian Cancer
• Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.

• Hospitals
• Research Institutes
• Other End Users

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

AbbVie, Inc.

Amgen Inc.

AstraZeneca plc

Bayer AG

Bristol-Myers Squibb Company

Eli Lilly

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V

Norvatis AG

Pfizer

Sanofi S.A.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY SOURCE

3.1 Market Overview by Source
3.2 Human
3.3 Humanized
3.4 Chimeric
3.5 Murine

4 SEGMENTATION OF ASIA PACIFIC MARKET BY CATEGORY

4.1 Market Overview by Category
4.2 Branded mAbs
4.3 Biosimilar mAbs

5 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCTION TYPE

5.1 Market Overview by Production Type
5.2 In Vitro Production
5.3 In Vivo Production

6 SEGMENTATION OF ASIA PACIFIC MARKET BY APPLICATION

6.1 Market Overview by Application
6.2 Cancer
  6.2.1 Breast Cancer
  6.2.2 Colorectal Cancer
  6.2.3 Lung Cancer
  6.2.4 Ovarian Cancer
  6.2.5 Other Cancer Types
6.3 Autoimmune Diseases
6.4 Inflammatory Diseases
6.5 Infectious Diseases
6.6 Other Applications

7 SEGMENTATION OF ASIA PACIFIC MARKET BY END USER

7.1 Market Overview by End User
7.2 Hospitals
7.3 Research Institutes
7.4 Other End Users

8 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY

8.1 Overview of Asia-Pacific Market
8.2 Japan
8.3 China
8.4 Australia
8.5 India
8.6 South Korea
8.7 Rest of APAC Region

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Monoclonal Antibodies Market in Balanced Perspective, 2019-2030
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. World Health Spending by Region, $ bn, 2013-2020
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Monoclonal Antibodies Market
Table 5. Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 6. Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, $ bn
Table 7. Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn
Table 8. Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 9. Asia Pacific Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn
Table 10. Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 11. APAC Monoclonal Antibodies Market by Country, 2019-2030, $ bn
Table 12. Japan Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 13. Japan Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 14. Japan Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 15. China Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 16. China Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 17. China Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 18. Australia Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 19. Australia Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 20. Australia Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 21. India Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 22. India Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 23. India Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 24. South Korea Monoclonal Antibodies Market by Source, 2019-2030, $ bn
Table 25. South Korea Monoclonal Antibodies Market by Application, 2019-2030, $ bn
Table 26. South Korea Monoclonal Antibodies Market by End User, 2019-2030, $ bn
Table 27. Monoclonal Antibodies Market in Rest of APAC by Country/Region, 2019-2030, $ bn
Table 28. Abbott Laboratories: Company Snapshot
Table 29. Abbott Laboratories: Business Segmentation
Table 30. Abbott Laboratories: Product Portfolio
Table 31. Abbott Laboratories: Revenue, 2018-2020, $ bn

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 4. Asia Pacific Monoclonal Antibodies Market, 2019-2030, $ bn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Monoclonal Antibodies Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Monoclonal Antibodies Market
Figure 10. Investment Opportunity Analysis
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Monoclonal Antibodies Market
Figure 12. Breakdown of Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue
Figure 13. Asia Pacific Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%)
Figure 14. Asia Pacific Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn
Figure 15. Asia Pacific Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn
Figure 16. Asia Pacific Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn
Figure 17. Asia Pacific Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn
Figure 18. Breakdown of Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue
Figure 19. Asia Pacific Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%)
Figure 20. Asia Pacific Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn
Figure 21. Asia Pacific Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn
Figure 22. Breakdown of Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue
Figure 23. Asia Pacific Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%)
Figure 24. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn
Figure 25. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn
Figure 26. Breakdown of Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue
Figure 27. Asia Pacific Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%)
Figure 28. Asia Pacific Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn
Figure 29. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn
Figure 30. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn
Figure 31. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn
Figure 32. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn
Figure 33. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn
Figure 34. Asia Pacific Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn
Figure 35. Asia Pacific Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn
Figure 36. Asia Pacific Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn
Figure 37. Asia Pacific Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn
Figure 38. Breakdown of Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue
Figure 39. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%)
Figure 40. Asia Pacific Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn
Figure 41. Asia Pacific Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn
Figure 42. Asia Pacific Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn
Figure 43. Breakdown of APAC Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue
Figure 44. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%)
Figure 45. Monoclonal Antibodies Market in Japan, 2019-2030, $ bn
Figure 46. Monoclonal Antibodies Market in China, 2019-2030, $ bn
Figure 47. Monoclonal Antibodies Market in Australia, 2019-2030, $ bn
Figure 48. Monoclonal Antibodies Market in India, 2019-2030, $ bn
Figure 49. Monoclonal Antibodies Market in South Korea, 2019-2030, $ bn
Figure 50. Monoclonal Antibodies Market in Rest of APAC, 2019-2030, $ bn
Figure 51. Growth Stage of Asia Pacific Monoclonal Antibodies Industry over the Forecast Period